Drug resistance in multiple myeloma

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Multiple myeloma (MM) is a plasma cell malignancy with evolving treatments.
• Despite advances, most patients relapse and develop drug resistance.
• New therapeutic strategies are needed to overcome resistance.

Purpose of the Study:

• To review the cellular, microenvironmental, and molecular mechanisms of drug resistance in multiple myeloma.
• To identify key factors contributing to treatment failure and relapse.
• To highlight the need for novel therapeutic approaches.

Main Methods:

• Literature review of current research on multiple myeloma drug resistance.
• Analysis of genetic and epigenetic alterations in resistant MM cells.
• Examination of apoptosis, senescence, and DNA repair pathway defects.
• Investigation of drug target alterations and microenvironmental influences.

Main Results:

• Genetic abnormalities and epigenetic aberrations (DNA methylation, histone modification) are central to MM drug resistance.
• Defects in apoptosis, senescence, and DNA repair pathways contribute significantly.
• Alterations in drug targets and the tumor microenvironment also play a role.
• Multiple factors contribute to the complex phenomenon of drug resistance.

Conclusions:

• A comprehensive understanding of MM drug resistance mechanisms is essential.
• Targeting these mechanisms can enhance current treatments and inform novel therapies.
• Further research into pathways and protein expression is critical for advancing MM treatment.